Journey Medical
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 58
- Market Cap
- $109.6M
- Introduction
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Journey Submits New Drug Application for DFD-29
Journey Medical Corporation submitted an NDA to the FDA for DFD-29, a potential oral treatment for rosacea's erythema and inflammatory lesions, developed with Dr. Reddy's Laboratories. Supported by positive phase 3 trial data, DFD-29 showed superiority over placebo and Oracea, with no significant safety issues reported.
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Journey Medical Corporation submitted an NDA to the FDA for DFD-29, a potential best-in-class oral treatment for rosacea's inflammatory lesions and erythema, supported by positive Phase 3 clinical data. DFD-29 showed superiority over current treatments and placebo in trials, aiming to improve the treatment paradigm for rosacea patients.
Journey Medical Corporation Announces Successful FDA Meeting Minutes Supporting DFD-29's NDA Submission for Rosacea Treatment
Journey Medical Corporation, in collaboration with Dr. Reddy’s Laboratories Ltd., received FDA meeting minutes supporting DFD-29's NDA submission for rosacea treatment. DFD-29, showing superiority in Phase 3 trials, aims for year-end 2023 NDA submission, targeting approval as a leading oral therapy for rosacea's inflammatory lesions and redness.
DFD-29 Bests Competition for Papulopustular Rosacea in Adults
Journey Medical plans to submit an NDA for DFD-29 to the FDA in 2023, following positive Phase 3 trial results showing DFD-29's superiority over Oracea and placebo in treating rosacea, with significant IGA success and lesion reduction, and no major safety issues.
© Copyright 2025. All Rights Reserved by MedPath